CNBX Pharmaceuticals Company Description
CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer.
Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome.
The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer.
In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test.
The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022.
CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Eyal Barad |
Contact Details
Address: #3 Bethesda Metro Center Bethesda, Nevada 20814 United States | |
| Phone | 877 424 2429 |
| Website | cnbxpharma.com |
Stock Details
| Ticker Symbol | CNBX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | September - August |
| Reporting Currency | USD |
| ISIN Number | US13764M1009 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eyal Barad | Co-Founder, Chief Executive Officer and Director |
| Gabriel Yariv | President, Chief Operating Officer and Executive Chairman |
| Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer |
| Dr. Sanja Goldberg | Chief Technology Officer |
| Dr. Sigalit Ariely-Portnoy Ph.D. | Senior Advisor of Regulation, Validation and Quality and Member of Advisory Board |
| Dr. Tal Mofkadi Ph.D. | Financial Advisor and Member of Advisory Board |
| Yasha Borstein | Chief Data Officer |
| Dr. Yaakov Waksman | Head of Cannabidiol Research |
| Dr. Ilya Reznik M.D. | Head of Neuropsychiatry Development |
| Dr. Lior Eshdat | Member of Scientific Advisory Board and Vice President of IP |